Cargando…

BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma

BACKGROUND: The molecular mechanisms driving the papillary thyroid carcinoma (PTC) are still poorly understood. The most frequent genetic alteration in PTC is the BRAFV600E mutation–its impact may extend even beyond PTC genomic profile and influence the tumor characteristics and even clinical behavi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rusinek, Dagmara, Swierniak, Michal, Chmielik, Ewa, Kowal, Monika, Kowalska, Malgorzata, Cyplinska, Renata, Czarniecka, Agnieszka, Piglowski, Wojciech, Korfanty, Joanna, Chekan, Mykola, Krajewska, Jolanta, Szpak-Ulczok, Sylwia, Jarzab, Michal, Widlak, Wieslawa, Jarzab, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666467/ https://www.ncbi.nlm.nih.gov/pubmed/26625260 http://dx.doi.org/10.1371/journal.pone.0143688

Ejemplares similares

Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Corrigendum: Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
por: Rusinek, Dagmara, et al.
Publicado: (2017)

Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
por: Rusinek, Dagmara, et al.
Publicado: (2018)

Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers – the role of Ct serum level
por: Jarzab, Barbara, et al.
Publicado: (2013)

The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAF(V600E) Mutation Status and Other Prognostic Factors
por: Czarniecka, Agnieszka, et al.
Publicado: (2015)

Novel TG‐FGFR1 and TRIM33‐NTRK1 transcript fusions in papillary thyroid carcinoma
por: Pfeifer, Aleksandra, et al.
Publicado: (2019)

Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma—Do They Exist?
por: Szpak-Ulczok, Sylwia, et al.
Publicado: (2020)

TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2020)

Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours
por: Wojtas, Bartosz, et al.
Publicado: (2017)

Gene signature of the post-Chernobyl papillary thyroid cancer
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2016)

Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues
por: Pfeifer, Aleksandra, et al.
Publicado: (2013)

Comparison of clinical examination with orbital MRI evaluation in patients with thyroid orbitopathy - do we need imaging and when?
por: Król, Aleksandra, et al.
Publicado: (2013)

Endogenous avidin biotin activity (EABA) in thyroid pathology: immunohistochemical study
por: Nikiel, Barbara, et al.
Publicado: (2009)

Prognostic value of lymph node metastases of differentiated thyroid cancer (DTC) according to the local advancement and range of surgical excision
por: Czarniecka, Agnieszka, et al.
Publicado: (2010)

Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use of (1)H HR MAS NMR spectroscopy
por: Skorupa, Agnieszka, et al.
Publicado: (2021)

Lobo-isthmectomy in the management of differentiated thyroid cancer
por: Krajewska, Jolanta, et al.
Publicado: (2023)

Current status of the prognostic molecular markers in medullary thyroid carcinoma
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2020)

Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma – Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015
por: Czarniecka, Agnieszka, et al.
Publicado: (2021)

Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma
por: Krajewska, Jolanta, et al.
Publicado: (2019)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021)

The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
por: Gawlik, Tomasz, et al.
Publicado: (2010)

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
por: Rostami, Elham, et al.
Publicado: (2017)

BRAFV600E and KIT immunoexpression in early-stage melanoma
por: Germano, Andressa, et al.
Publicado: (2019)

Sequence of therapies for advanced BRAFV600E/K melanoma
por: Gonzalez-Cao, Maria, et al.
Publicado: (2023)

13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2009)

A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping
por: Fujarewicz, Krzysztof, et al.
Publicado: (2007)

Impact of SNPs on methylation readouts by Illumina Infinium HumanMethylation450 BeadChip Array: implications for comparative population studies
por: Daca-Roszak, Patrycja, et al.
Publicado: (2015)

Association between Age at Diagnosis of Graves' Disease and Variants in Genes Involved in Immune Response
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2013)

Analysis options for high-throughput sequencing in miRNA expression profiling
por: Stokowy, Tomasz, et al.
Publicado: (2014)

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
por: Kukulska, Aleksandra, et al.
Publicado: (2010)

BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
por: Chen, Brenden, et al.
Publicado: (2012)

Lack of BRAFV600E mutation in stage I and II of colorectal cancer
por: Molaei, Mahsa, et al.
Publicado: (2016)

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
por: del Bufalo, Francesca, et al.
Publicado: (2014)

The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas
por: Li, Yangsen, et al.
Publicado: (2022)

The Association of SNPs Located in the CDKN2B-AS1 and LPA Genes With Carotid Artery Stenosis and Atherogenic Stroke
por: Lasek-Bal, Anetta, et al.
Publicado: (2019)

Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance
por: Oikonomou, Eftychia, et al.
Publicado: (2011)

Differential expression of HSPA1 and HSPA2 proteins in human tissues; tissue microarray-based immunohistochemical study
por: Scieglinska, Dorota, et al.
Publicado: (2011)

Concentrations of Selected Adipokines, Interleukin-6, and Vitamin D in Patients with Papillary Thyroid Carcinoma in Respect to Thyroid Cancer Stages
por: Warakomski, Jakub, et al.
Publicado: (2018)

Overproduction of thrombopoietin by BRAFV600E‐mutated mouse hepatocytes and contribution of thrombopoietin to hepatocarcinogenesis
por: Tanaka, Hiroki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iede9q7379pi9b6e1c588efctf